Leslie Gordon, MD, PhD
Plasma progerin changes with lonafarnib therapy -association with drug effect and extended survival
Medical Director and Chair, Organizing Committee,The Progeria Research Foundation, Brown University, Hasbro Children’s Hospital, Boston Children’s Hospital, and Harvard Medical School- Boston, MA
Vicente Andrés, PhD
Smooth muscle or endothelium: which is to blame for precocious vascular disease and death in HGPS?
Professor, Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)- Madrid, Spain
Sammy Basso, MSc
Spokesperson, Sammy Basso’s Italian Association for Progeria; International Ambassador,
Progeria Research Foundation; Coordinator, Italian Network for Laminopathies – Italy
Abigail Buchwalter, PhD
Combined proteome-wide measurements of protein and cell turnover across tissues accounts for the tissue specificity of progeria
Assistant Professor, Cardiovascular Research Institute and the Department of Physiology at the University of California- San Francisco, CA
Francis Collins, MD, PhD
Racing for progeria cures with RNA and DNA therapies
Special Advisor to the President for Special Projects
John Cooke, MD, PhD
DNA Damage in Progeria, and its Reversal by Telomerase
Joseph C. “Rusty” Walter and Carole Walter Looke Presidential Distinguished Chair; Professor and Chair, Department of Cardiovascular Sciences; Director, Center for Cardiovascular Regeneration; Medical Director, Center for RNA Therapeutics; Chief Translational Officer, Houston Methodist Academic Institute – Houston, TX
Mario Cordero, PhD
Lessons from the inflammasomes in the pathophysiology of Progeria
Researcher, Biomedical Research and Innovation Institute of Cadiz (INIBICA)- Cadiz, Spain
Epigenetics of Aging, Department of Dermatology and Allergy, TUM school of Medicine, Technical University of Munich (TUM), Germany.
Maria Eriksson, PhD
Transient base editor expression corrects the progeria mutation in mice
Professor, Karolinska Institutet- Huddinge, Sweden
Endothelial and systemic upregulation of miR-34a-5p fine-tunes senescence in progeria
Professor, Medical University Vienna, Max Perutz Labs – Vienna, Austria
Jay Humphrey, PhD
Evolving vascular phenotypes and cardiovascular consequences in a mouse model of HGPS and its treatment
Professor, Department of Biomedical Engineering Yale University- New Haven, CT
David R. Liu, PhD
Precision Genome Editing and Progeria
Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, Director of the Chemical Biology and Therapeutic Sciences Program, Core Institute Member and Vice-Chair of the Faculty, Broad Institute. Investigator, Howard Hughes Medical Institute, Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry & Chemical Biology, Harvard University – Boston, MA
Bae-Hoon Kim, PhD
Updating the development progress of progerinin, inhibitor of progerin
Research Director of Rare Disease R&D Center, PRG Science and Technology – Korea
Monica Kleinman, MD
Everolimus plus lonafarnib clinical trial outcomes
Clinical Director, Medical/Surgical Intensive Care Unit; Medical Director, Transport Program; Senior Associate in Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital and Harvard Medical School – Boston, MA
Chiara Lanzulo, PhD
Genome function’s recovery upon pharmacological treatments in Hutchinson Gilford Progeria Syndrome
Senior researcher, Institute of Biomedical Technologies (ITB)-CNR, Chromatin and Nuclear architecture Laboratory at Istituto Nazionale di Genetica Molecolare – Milan, Italy
Giovanna Lattanzi, PhD
Adipocyte-specific effects of drug treatments in HGPS
Research Director, CNR Institute of Molecular Genetics- Bologna, Italy
Elsa Logarinho, PhD
Small-molecule correction of microtubule-dependent genotoxic stress in HGPS cells bypasses progerin-driven cellular phenotypes
Researcher, Instituto de Biologia Molecular e Celular (IBMC) Instituto de Inovação e Investigação em Saúde- Porto, Portugal
Emma McCullagh, PhD
Preclinical Toxicology Specialist, Domain Biotechnologies- Austin, TX
Pedro J. del Nido, MD
Chairman, Department of Cardiac Surgery Boston Children’s Hospital; William E. Ladd Professor of Child Surgery, Harvard Medical School
Srinivasan Mukundan, MD, PhD
Medical Director, Reveal Pharmaceuticals – Cambridge, MA
Valerio Orlando, PhD
Repeatome RNA: from junk to therapeutics for premature aging and tissue regeneration
Professor of Epigenetics, Head of KAUST Environmental Epigenetics Research Program -Saudi Arabia
George Truskey, PhD
Effect of Adenine Base Editing on the Function of a Tissue-Engineered Vascular Model of HGPS
R. Eugene and Susie E. Goodson Professor of Biomedical Engineering Duke University Durham – North Carolina, USA
Sign Up
for Our
Newsletter!
Together, we
WILL
find the cure!
